Thomas D. Meek

7.0k citations

70 papers · 5.3k indexed · 2 hit papers · h-index 33

Co-authors: David L. Pompliano Robert A. Copeland Thaddeus A. Tomaszek Christine Debouck Geoffrey A. Holdgate Rachel L. Grimley Brian W. Metcalf James E. Strickler
Topics: HIV/AIDS drug development and treatment (26 papers)HIV Research and Treatment (22 papers)Biochemical and Molecular Research (18 papers)
Cited by: Virology Infectious Diseases Computational Theory and Mathematics
Journals: Nature Proceedings of the National Academy of Sciences Journal of the American Chemical Society
Partner nations: United States New Zealand United Kingdom

In The Last Decade

Thomas D. Meek

69 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug–target residence time and its implications for lead optimization

2006 1.1k citations Robert A. Copeland, David L. Pompliano et al. Nature Reviews Drug Discovery profile →
Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase

1999 887 citations Ishrut Hussain, David J. Powell et al. Molecular and Cellular Neuroscience profile →

Peers

Countries citing papers authored by Thomas D. Meek

Since Specialization

Citations

This map shows the geographic impact of Thomas D. Meek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas D. Meek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas D. Meek more than expected).

Fields of papers citing papers by Thomas D. Meek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas D. Meek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas D. Meek. The network helps show where Thomas D. Meek may publish in the future.

Co-authorship network of co-authors of Thomas D. Meek

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas D. Meek. A scholar is included among the top collaborators of Thomas D. Meek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas D. Meek. Thomas D. Meek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Kinetic and Structural Characterization of Trypanosoma cruzi Hypoxanthine–Guanine–Xanthine Phosphoribosyltransferases and Repurposing of Transition-State Analogue Inhibitors 2023 ·Biochemistry ·(unknown),Kathleen M. Meneely,(unknown),(unknown),(unknown),(unknown),Keith Clinch,(unknown),Audrey L. Lamb,Peter C. Tyler,Thomas D. Meek,(unknown)	2
2	Characterization of adenine phosphoribosyltransferase (APRT) activity in Trypanosoma brucei brucei: Only one of the two isoforms is kinetically active 2022 ·PLoS neglected tropical diseases ·(unknown),Thomas D. Meek,(unknown)	5
3	Kinetic Characterization and Inhibition of Trypanosoma cruzi Hypoxanthine–Guanine Phosphoribosyltransferases 2022 ·Biochemistry ·(unknown),(unknown),(unknown),(unknown),Keith Clinch,(unknown),(unknown),Vern L. Schramm,Peter C. Tyler,Thomas D. Meek,(unknown)	9
4	The design of protozoan phosphoribosyltransferase inhibitors containing non-charged phosphate mimic residues 2022 ·Bioorganic & Medicinal Chemistry ·(unknown),(unknown),Karl J. Shaffer,Wanting Jiao,(unknown),(unknown),(unknown),(unknown),Thomas D. Meek,Vern L. Schramm,Peter C. Tyler	1
5	Mechanism-based inactivator of isocitrate lyases 1 and 2 from Mycobacterium tuberculosis 2017 ·Proceedings of the National Academy of Sciences ·(unknown),Andrew S. Murkin,(unknown),Lawrence D. Harris,Peter C. Tyler,(unknown),James C. Sacchettini,(unknown),Thomas D. Meek	32
6	Mechanistic enzymology in drug discovery: a fresh perspective 2017 ·Nature Reviews Drug Discovery ·Geoffrey A. Holdgate,Thomas D. Meek,Rachel L. Grimley	153
7	Drug–target residence time and its implications for lead optimizationbreakdown → 2006 ·Nature Reviews Drug Discovery ·Robert A. Copeland,David L. Pompliano,Thomas D. Meek	1098
8	ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the β-Secretase Site 2000 ·Molecular and Cellular Neuroscience ·Ishrut Hussain,David J. Powell,David Howlett,Gayle A. Chapman,(unknown),Paul R. Murdock,David G. Tew,Thomas D. Meek,C.G. Chapman,Klaus Schneider,(unknown),Daniel Tattersall,(unknown),Christopher Southan,D. M. Ryan,David L. Simmons,F S Walsh,C. Dingwall,Gary Christie	131
9	[9] Use of steady state kinetic methods to elucidate the kinetic and chemical mechanisms of retroviral proteases 1994 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Thomas D. Meek,(unknown),Thelma S. Angeles	19
10	Inhibitor binding to the Phe53Trp mutant of HIV-1 protease promotes conformational changes detectable by spectrofluorometry 1993 ·Biochemistry ·(unknown),Christine Debouck,Ingrid C. Deckman,Husam M. Abu‐Soud,Frank M. Raushel,Thomas D. Meek	35
11	Use of nitrogen-15 kinetic isotope effects to elucidate details of the chemical mechanism of human immunodeficiency virus 1 protease 1993 ·Biochemistry ·(unknown),Thelma S. Angeles,Thomas D. Meek	45
12	Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, x-ray crystallography, and infected T-cell assays 1992 ·Biochemistry ·Geoffrey B. Dreyer,Dennis M. Lambert,Thomas D. Meek,Thomas J. Carr,Thaddeus A. Tomaszek,Annabellee V. Fernandez,H F Bartus,(unknown),(unknown)	110
13	Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV proteases 1992 ·Biochemistry ·(unknown),Ingrid C. Deckman,Jeffrey S. Culp,Michael D. Minnich,Ian Brooks,Preston Hensley,Christine Debouck,Thomas D. Meek	78
14	Solvent isotope partitioning: a new kinetic tool for the determination of desorption rates of reactant water from enzyme-substrate complexes in proteases 1992 ·Biochemistry ·Thelma S. Angeles,Gordon C. K. Roberts,Steven A. Carr,Thomas D. Meek	3
15	Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease 1991 ·Biochemistry ·(unknown),Ingrid C. Deckman,Michael D. Minnich,Jeffrey S. Culp,Samuel P. Franklin,Geoffrey B. Dreyer,Thaddeus A. Tomaszek,Christine Debouck,Thomas D. Meek	42
16	Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism 1991 ·Biochemistry ·(unknown),Thaddeus A. Tomaszek,Thomas D. Meek	199
17	HIV‐1 Protease as a Potential Target for Anti‐AIDS Therapy 1990 ·Annals of the New York Academy of Sciences ·Thomas D. Meek,Geoffrey B. Dreyer	14
18	A radiometric assay for HIV-1 protease 1990 ·Analytical Biochemistry ·(unknown),Brian D. Dayton,Michael L. Moore,Arthur Y. L. Shu,J. Richard Heys,Thomas D. Meek	22
19	Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli 1989 ·Proteins Structure Function and Bioinformatics ·James E. Strickler,Joselina Gorniak,Brian D. Dayton,Thomas D. Meek,M. Lane Moore,Victoria W. Magaard,John Malinowski,Christine Debouck	57
20	cis-4-Carboxy-6-(mercaptomethyl)-3,4,5,6-tetrahydropyrimidin-2(1H)-one, a potent inhibitor of mammalian dihydroorotase 1988 ·Journal of Medicinal Chemistry ·Jerry L. Adams,Thomas D. Meek,Shau Ming Mong,Randall K. Johnson,Brian W. Metcalf	34

About Thomas D. Meek

Thomas D. Meek is a scholar working on Virology, Infectious Diseases and Molecular Biology, having authored 70 papers that have together received 5.3k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (26 papers), HIV Research and Treatment (22 papers) and Biochemical and Molecular Research (18 papers). The work is most often cited by research in Virology (1.1k citations), Infectious Diseases (1.4k citations) and Computational Theory and Mathematics (756 citations). Thomas D. Meek has collaborated with scholars based in United States, New Zealand and United Kingdom. Frequent co-authors include David L. Pompliano, Robert A. Copeland, Thaddeus A. Tomaszek, Christine Debouck, Geoffrey A. Holdgate, Rachel L. Grimley, Brian W. Metcalf, James E. Strickler, Geoffrey B. Dreyer and David G. Tew. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact